Trial
NCT04287348
Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept
Phase IVTERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Vista Klinik
Collaborators
Novartis
Condition
Neovascular Age-related Macular Degeneration
Intervention
Brolucizumab 6 mg solution for intravitreal injection
Why stopped
due to safety letter beovu from Novartis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-12-29